Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002
Gabather AB (Nasdaq First North Growth Market: GABA) announces today that the company has received approval from the Portuguese regulatory authority, INFARMED, to start the target-engagement study in healthy volunteers with the drug candidate GT-002. Screening and recruitment of individuals will start shortly.
GT-002 is our most advanced selective GABAA receptor modulator with a unique mechanism of action that opens for the development of new and effective drugs against several neuropsychiatric diagnoses.
In the double-blind, placebo-controlled phase 1 study, healthy subjects will receive GT-002 in a so-called cross-over design study where the effect of GT-002 will be examined with electroencephalography (EEG) and magnetic resonance imaging (fMRI). The aim of the study is to investigate the effects of GT-002 on EEG signals and the location of the signals in the human brain.
"We welcome this positive news from the Portuguese Medicines Agency and look forward to start the clinical trial with our drug candidate," says Michael-Robin Witt, CEO of Gabather.
For further information, please contact:
Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: [email protected]
Briefly about Gabather AB
Based on pioneering research at Lund University and the Research Institute for Biological Psychiatry in Roskilde, Gabather was founded in 2014 with the aim of developing innovative and effective therapies for neuropsychiatric disorders. Our research and development focus on developing new pro-cognitive drug candidates targeting the GABAA receptor for the treatment of disorders and imbalances in the central nervous system (CNS). GABAA receptors are the main inhibitory signalling system in the brain that regulates central CNS functions. Dysfunction or imbalance in this system is known to be at the core of many neurological and neuropsychiatric disorders.
The Company's Certified Adviser is Erik Penser Bank, tel. 08- 463 80 00, [email protected]
